New cell therapy IMV102 targets Hard-to-Treat multiple myeloma in early trial
NCT ID NCT07493135
First seen Mar 25, 2026 · Last updated May 24, 2026 · Updated 11 times
Summary
This early-phase study tests a new treatment called IMV102 in 30 people with multiple myeloma that has returned or not responded to at least three prior therapies. Participants receive a single infusion of IMV102, and researchers will monitor safety and how well it controls the cancer over 24 months. The goal is to see if this cell therapy is safe and shows promise for this difficult-to-treat blood cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Boren Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
NOT_YET_RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The second affiliated hospital of Chongqing medical university
NOT_YET_RECRUITINGChongqing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhengzhou Yihe Hospital
NOT_YET_RECRUITINGZhengzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.